Egis is inaugurating new research and development buildings today

Membres | 25 septembre 2012


Budapest, September 25, 2012 

Egis is inaugurating new research and development buildings today

Egis  Pharmaceuticals  PLC  has  expanded  its  production  site  located  in  Budapest’s  16th district with two new R&D investments. The company’s strategic goal is to launch more products in a shorter time with the help of its drug development centers. The company has constructed its new Pharmaceutical Development Laboratory & Pilot Plant and its new Analytical Development Laboratory in accordance with this. The new investments are  going  to  be  inaugurated  on  September  25  by  Hungary’s  Prime  Minister  Viktor Orbán.

As a result of the altogether HUF 7 billion investments, which have received HUF 226 million government subsidy, a total of nine thousand square-meter research  and development center will  be  inaugurated  at  Egis  PLC’s  production  site  located  in  Budapest’s  16th district. The investments  together  create  new  jobs  for  more  than  fifty  highly  qualified  professionals  and provide a cutting-edge working environment for a total of 135 people. The creation of the new R&D capacities has largely been facilitated by the fact that the Hungarian government allowed the research and development related write-offs from the pharmaceutical extra taxes.

Through  the  investments,  a  new,  3500-square-meter  Pharmaceutical  Development Laboratory & Pilot Plant will be inaugurated today. It is twice as big as the former facility with four times as many clean areas and doubled pilot production capacity. The other facility to be inaugurated today is the 5500-square-meter Analytical Development Laboratory, which – in line with the increased capacity of the new Pharmaceutical Development Laboratory & Pilot Plant – provides analytical support and by so, it further accelerates product development. In addition,  Egis’  new  analytical  testing  laboratory  carrying  out  tests  that  are  essential  to  the marketing of biosimilar products has also been constructed here. This project is co-financed by the European Regional Development Fund with a support of HUF 97 million.

About Egis Pharmaceuticals PLC

Egis  is  one  of  the  leading  pharmaceutical  companies  in  Hungary  and  the  Central  Eastern European region. The company’s history dates back to nearly a century and its activities extend to  every  field  of  pharmaceutical  production  from  research  and  development  through  the production of APIs and finished products to sales. It has carried out research and development activities  and  production  of  active  pharmaceutical  ingredients  and  finished  products  only  in Hungary since the foundation of the company.  In the past twenty years it has dedicated HUF 130  billion  to  investments.  76%  of  the  company’s  turnover  derives  from  export  and  its products are sold to more than 60 countries in the world, out of which Egis has representative offices  and  subsidiaries  in  18  countries.  Egis  employs  nearly  4000  people  at  its  Hungarian production sites and foreign offices and it is the 26th biggest employer in Hungary. The company dedicates an increasingly significant amount, 9% of its turnover to research and development, which amounted to HUF 11.6 billion in the 2010/2011 business year. With this Egis  dedicates  the 4th largest  sum  to  innovation  among  the  companies  of  Central  Eastern Europe.

Nos membres bienfaiteurs

    • Accor
    • Auchan
    • Axon
    • Axéréal
    • BNP Paribas
    • Capgemini
    • Citroën
    • Danone
    • EGIS
    • EMT
    • GDF-SUEZ
    • Gide Loyrette Nouel
    • Groupama
    • Kempinski Hotel Budapest Zrt.
    • Lapker
    • Lesaffre
    • Master MBA MAE
    • Peugeot
    • Renault
    • Sanofi-Aventis
    • Schneider Electric
    • Servier
    • Valeo
    • Veolia

Nous contacter

Adresse : 1088 Budapest, Rákóczi út 1-3. East West Business Center, 3ème étage
Tél : (+36 1) 317 82 68
Fax : (+36 1) 338 41 74
Email : ccifh(at)

Nos partenaires

© 2015 CCIFH